Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet

被引:34
作者
Shakibaei, M
de Souza, P
van Sickle, D
Stahlmann, R
机构
[1] Free Univ Berlin, Inst Anat, D-14195 Berlin, Germany
[2] Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN USA
[3] Free Univ Berlin, Dept Toxicol, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany
关键词
ciprofloxacin; dog; tendon; magnesium; extracellular matrix;
D O I
10.1007/s002040100243
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Quinolones are antibacterial agents that have the potential to induce Achilles tendon disorders - such as tendinitis or even ruptures - in patients treated with these drugs. We studied the effects of ciprofloxacin on several proteins of Achilles tendons from immature dogs, 10- to 11-weeks-old. The dogs were treated orally for 5 days with 30 or 200 mg ciprofloxacin/kg body weight or with the vehicle alone. Since quinolone-like alterations in joint cartilage were observed in magnesium-deficient animals, another group was fed a magnesium-deficient diet for 6 weeks. At necropsy, tendons (n = 3 from each group) were frozen and stored until analysis when they were homogenized in a lysis buffer to release a soluble fraction of the tendon proteins. Densitometric analysis of the immunoblots with anticollagen type I, anti-elastin, anti-fibronectin, and antiintegrin antibodies showed a significant reduction of all proteins. For example, collagen type I concentrations (mean SD, arbitrary densitometric units) were 3190 +/- 217 (controls), 1890 +/- 468 (30 mg/kg), 1695 +/- 135 (200 mg/kg) and 2053 +/- 491 in the magnesium-deficient dogs. The differences between concentrations in controls and all treated groups were statistically significant (P <0.01, t-test). Similarly, compared with control samples, relative concentrations of other proteins in tendons from ciprofloxacin-treated dogs (30 mg/kg) decreased by 73% (elastin), 88% (fibronectin), and 96% (beta (1) integrin) (data from low-dose group only). A very similar pattern of protein alterations was detected in samples from magnesium-deficient dogs. In conclusion, rather low doses of a fluoroquinolone or a diet-induced magnesium deficiency caused similar biochemical alterations in the soluble fraction of proteins from canine tendons. These findings support our hypothesis that quinolone-induced toxic effects on connective tissue structures are due to the magnesium-antagonistic effects of these antibacterial agents. They also indicate that patients with a latent magnesium deficiency could be at an increased risk of quinolone-induced tendon disorders.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 30 条
  • [1] BAILEY RR, 1983, NEW ZEAL MED J, V96, P590
  • [2] BORDERIE P, 1992, REV RHUM MAL OSTEO, V59, pE22
  • [3] TYROSINE PHOSPHORYLATION OF PAXILLIN AND PP125(FAK) ACCOMPANIES CELL-ADHESION TO EXTRACELLULAR-MATRIX - A ROLE IN CYTOSKELETAL ASSEMBLY
    BURRIDGE, K
    TURNER, CE
    ROMER, LH
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (04) : 893 - 903
  • [4] Tendinitis associated with ciprofloxacin
    Carrasco, JM
    Garcia, B
    Andujar, C
    Garrote, F
    deJuana, P
    Bermejo, T
    [J]. ANNALS OF PHARMACOTHERAPY, 1997, 31 (01) : 120 - 120
  • [5] Integrins on joint cartilage chondrocytes and alterations by ofloxacin or magnesium deficiency in immature rats
    Forster, C
    Kociok, K
    Shakibaei, M
    Merker, HJ
    Vormann, J
    Gunther, T
    Stahlmann, R
    [J]. ARCHIVES OF TOXICOLOGY, 1996, 70 (05) : 261 - 270
  • [6] REGULATION OF ALPHA-2-BETA-1-MEDIATED FIBROBLAST MIGRATION ON TYPE-I COLLAGEN BY SHIFTS IN THE CONCENTRATIONS OF EXTRACELLULAR MG2+ AND CA2+
    GRZESIAK, JJ
    DAVIS, GE
    KIRCHHOFER, D
    PIERSCHBACHER, MD
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 117 (05) : 1109 - 1117
  • [7] Fluoroquinolone-induced tendinopathy: What do we know?
    Harrell, RM
    [J]. SOUTHERN MEDICAL JOURNAL, 1999, 92 (06) : 622 - 625
  • [8] A REAPPRAISAL OF QUINOLONE TOLERABILITY - THE EXPERIENCE OF THEIR MUSCULOSKELETAL ADVERSE-EFFECTS
    HAYEM, G
    CARBON, C
    [J]. DRUG SAFETY, 1995, 13 (06) : 338 - 342
  • [9] HOOPER DC, 2000, PRINCIPLES PRACTICE, P404
  • [10] Kahn MF, 1997, REV RHUM, V64, P437